摘要
目的观察奥氮平在乳腺癌新辅助化疗中的止吐疗效。方法方便选取2014年9月—2016年4月该院采用CET新辅助化疗的乳腺癌患者100例,随机分为两组,各50例。两组均帕洛诺司琼、地塞米松止吐,观察组同时加用奥氮平止吐。比较两组控制急性和延迟性恶心、呕吐的疗效、不良反应,及化疗前后的体重变化。结果观察组急性、延迟性恶心、呕吐控制有效率分别为92%,76%,均高于对照组的74%,54%,差异有统计学意义(P<0.05)。观察组体重变化有效率32%,比对照组有效率22%高,但两组差异无统计学意义(P>0.05)。两组不良反应均较轻微。结论奥氮平提高了乳腺癌新辅助化疗止吐疗效。
Objective This paper tries to explore the antiemetic efficacy of olanzapine in breast cancer neoadjuvant chemotherapy. Methods 100 breast cancer patients from September 2014 to April 2016 received CET neoadjuvant chemotherapy were convenient selected and randomly divided into two groups with 50 cases in each group. The two groups were all given palonosetron and dexamethasone, and the observation group was combined with olanzapine simultaneously, to prevent nausea and vomiting. The remission effect and adverse reactions of the two groups in the control of acute and delayed nausea and vomiting, and the changes of body weight before and after chemotherapy were compared. Results In acute and delay nausea and vomiting period, the remission rate in the observation group were 92% and 76%, obviously higher than that in control group of 74% and 54%, the differences were statistically significant（P0.05）. The weight change rate of the observation group was 32%, higher than that of the control group of 22%, but the difference was no statistically significant（P0.05）. The adverse reactions of the two groups were few. Conclusion Antiemetic therapy containing olanzapine can increase the antiemetic efficacy in breast cancer neoadjuvant chemotherapy.
出处
《中外医疗》
2017年第22期118-120,共3页
China & Foreign Medical Treatment
关键词
奥氮平
乳腺癌
新辅助化疗
止吐
Olanzapine
Breast cancer
Neoadjuvant chemotherapy
Antiemetic
